The Limitations and Risks Associated With Semaglutide Treatment-Reply.
Shi, Ivy, Sadiya S Khan, and Dhruv S Kazi. 2025. “The Limitations and Risks Associated With Semaglutide Treatment-Reply.”. JAMA Cardiology 10 (7): 749.
Search
Search results
254 results found
Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction.
DeJong, Colette, Kosuke Inoue, Matthew S Durstenfeld, Anubha Agarwal, Justin C Chen, Chien-Wen Tseng, Adams Dudley, Priscilla Y Hsue, and Dhruv S Kazi. 2025. “Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction.”. JACC. Heart Failure 13 (7): 102380.
An International, Expert-based, Multispecialty Delphi Consensus Document on Stroke Risk Stratification and the Optimal Management of Patients with Asymptomatic and Symptomatic Carotid Stenosis.
Paraskevas, Kosmas I, Ali F AbuRahma, Wesley S Moore, Peter Gloviczki, Bruce A Perler, Daniel G Clair, Christopher J White, et al. 2025. “An International, Expert-Based, Multispecialty Delphi Consensus Document on Stroke Risk Stratification and the Optimal Management of Patients With Asymptomatic and Symptomatic Carotid Stenosis.”. Journal of Vascular Surgery.
Ticagrelor Paradox: Systematic Review and Network Meta-Analysis.
Watanabe, Atsuyuki, Tadao Aikawa, Yoshihisa Miyamoto, Hiroki A Ueyama, Tomohiro Fujisaki, Satoshi Shoji, Kaveh Hosseini, et al. 2025. “Ticagrelor Paradox: Systematic Review and Network Meta-Analysis.”. Journal of the American Heart Association 14 (17): e041959.
Images in Vascular Medicine: Stenosis of the distal aorta unmasked by hemodynamic measures.
Andrassy, Martin, Eric Secemsky, and Grigorios Korosoglou. 2025. “Images in Vascular Medicine: Stenosis of the Distal Aorta Unmasked by Hemodynamic Measures.”. Vascular Medicine (London, England), 1358863X251351553.
Identifying predictors of durable treatment response among patients with claudication: A secondary analysis of the CLEVER trial.
Hentati, Firas, Brett J Carroll, Timothy P Murphy, Madeleine R Murphy, and Eric A Secemsky. 2025. “Identifying Predictors of Durable Treatment Response Among Patients With Claudication: A Secondary Analysis of the CLEVER Trial.”. Vascular Medicine (London, England) 30 (4): 431-38.
The Data We Overlook, the Insights We Miss: Rethinking Vascular Research.
Dubosq-Lebaz, Maxime, Eric A Secemsky, and Yann Gouëffic. 2025. “The Data We Overlook, the Insights We Miss: Rethinking Vascular Research.”. European Journal of Vascular and Endovascular Surgery : The Official Journal of the European Society for Vascular Surgery 70 (3): 284-86.
Threats to Patient Safety From Cybersecurity Flaws-A New Never Event.
Kramer, Daniel B, Jennifer R Amos, Julian M Goldman, and Kevin Fu. 2025. “Threats to Patient Safety From Cybersecurity Flaws-A New Never Event.”. JAMA 334 (5): 391-92.
PRIME 2.0: Proposed Requirements for Cardiovascular Imaging-Related Multimodal-AI Evaluation: An Updated Checklist.
Kagiyama, Nobuyuki, Márton Tokodi, Quincy A Hathaway, Rima Arnaout, Rhodri Davies, Damini Dey, Nicolas Duchateau, et al. 2025. “PRIME 2.0: Proposed Requirements for Cardiovascular Imaging-Related Multimodal-AI Evaluation: An Updated Checklist.”. JACC. Cardiovascular Imaging.
Multi-source analyses of average treatment effects with failure time outcomes.
Wen, Lan, Jon A Steingrimsson, Sarah E Robertson, and Issa J Dahabreh. 2025. “Multi-Source Analyses of Average Treatment Effects With Failure Time Outcomes.”. Lifetime Data Analysis.